Abstract

Anthralin, a relatively old topical medication, has not received much attention in America until recently, in spite of good results from its use in psoriasis and other chronic dermatoses. The present study involves treatment of 22 resistant psoriatics with a modification of the Ingram regimen, with most patients in the hospital under observation. Response was characterized by early rapid flattening of plaques and a significant reduction in total time required for clearing when compared to responses of previous conventional therapy. Side effects were seldom significant. Histologic changes during treatment reflected the rapid response to therapy. A review of the literature on the mechanism of action of anthralin reveals that it may function as a mitotic inhibitor of the epidermis.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.